StemGenex® Announces New Stem Cell Clinical Study for Multiple Sclerosis
La Jolla, CA (PRWEB) June 17, 2014 -- StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.
This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex’ multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.
Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."
This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, “It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.”
Rita Alexander, founder and president of StemGenex, stated, “This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDole’s research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.”
Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinson’s and Alzheimer’s disease, stroke recovery and others.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com
Public Relations, StemGenex®, http://www.stemgenex.com, +1 800-609-7795 Ext: 1002, [email protected]
Share this article